Bio-Rad Announces the Global Launch of the CFX Opus 96 and CFX Opus 384 Real-Time PCR Systems and BR.io, Web-Based Data Management and Analysis Software

HERCULES, Calif. – Bio-Rad Laboratories, Inc.,  (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products today announced the global launch of its CFX Opus 96 and CFX Opus 384 Real-time PCR Systems along with BR.io, a cloud-based instrument connectivity, data management, and analysis platform.

The CFX Opus 96 and CFX Opus 384 Real-Time PCR Systems represent the next generation of the company’s CFX Real-Time PCR Systems that are used in research and genomic testing as well as in pathogen detection and infectious disease testing. The CFX Opus 96 and CFX Opus 384 Real-Time PCR Systems employ the same optical design used across Bio-Rad’s portfolio of CFX products and offer enhanced usability with features designed for academic, commercial, and biopharma labs to conduct basic and translational research, process development, and quality control.

"The CFX Opus Systems expand the Bio-Rad family of life science tools, helping our customers find answers to complex biological questions," said Annette Tumolo, Bio-Rad Executive Vice President and President Life Science Group. "The addition of BR.io cloud connectivity offers customers a simplified qPCR experience and demonstrate Bio-Rad’s commitment to developing robust solutions to meet customers’ needs within the ever-evolving landscape of genomics research and diagnostics," she said.

Along with the launch, Bio-Rad also announces early access to BR.io, a cloud-based software that enables users to design experiments, analyze data, and access their experiments remotely. The integration with BR.io provides seamless data transfer and the ability for users to monitor instrument status anywhere from the cloud.

Bio-Rad's entire line of CFX systems have been instrumental to the company’s global response to the COVID-19 pandemic. The CFX Opus 96 and CFX Opus 384 Real-Time PCR Systems will further strengthen our contribution as we continue to work with our customers and governments around the world to fight this disease.

About the CFX Opus 96 and CFX Opus 384 Real-Time PCR Systems

  • Patent-pending block design delivers tight thermal uniformity for improved well-to-well consistency during real-time PCR experiments
  • Redesigned touchscreen interface and flexible connectivity options provide an intuitive and efficient experience for real-time PCR users
  • The same proprietary real-time PCR optical design

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.3 billion in 2019. For more information, please visit bio-rad.com.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products and about the CFX Opus 96 and CFX Opus 384 Systems further strengthening our contribution as we continue to work with our customers and governments around the world to fight the COVID-19 pandemic. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Investor Contact:
Kevin Han, Senior Director
Investor Relations
510-741-6777
ir@bio-rad.com

Media Contact:
Tina Cuccia, Manager
Corporate Communications
510-741-6063
tina_cuccia@bio-rad.com

Back to news